<DOC>
	<DOCNO>NCT02107092</DOCNO>
	<brief_summary>Subjects complete Double-blind Randomized Maintenance Phase ( DBRMP ) Study Day 29 visit ZS-004 ( NCT 02088073 ) i-STAT potassium value 3.5 6.2 mmol/l inclusive discontinue ZS-004 due hypo- hyperkalemia DBRMP mean i-STAT potassium value two consecutive measurement 0 60 minute Acute Phase Day 1/Maintenance Phase Day 1 3.5 6.2 mmol/l inclusive may option participate ZS-004E ( NCT 021070920 ) . Subjects discontinue study ZS-004 due reason ( e.g . adverse event , poor compliance , investigator decision ) enter study ZS-004E . All subject continue extension study must begin dose within two ( 2 ) day last dose investigational product ZS-004 .</brief_summary>
	<brief_title>Open-label Safety &amp; Efficacy ZS ( Sodium Zirconium Cyclosilicate ) 10g qd Extend Study ZS-004 Hyperkalemia .</brief_title>
	<detailed_description>All subject i-STAT potassium value 3.5-5.5 mmol/l , inclusive ZS-004 ( NCT 02088073 ) DBRMP Study Day 29 visit , continue directly open-label extension study ZS-004E ( NCT 021070920 ) , enter Maintenance Phase ( MP ) start open-label ZS dose 10g qd . All subject i-STAT potassium value &gt; 5.5 mmol/l ZS-004 DBRMP Study Day 29 visit undergo acute treatment phase ( AP ) receive ZS 10g three time day ( tid ) 24 ( 3 dos ) 48 hour ( 6 dos ) . If subject 's i-STAT potassium 3.5-5.0 mmol/l , inclusive 24 ( AP Study Day 2 ) 48 hour ( AP Study Day 3 ) , subject enter MP start dose 10g qd . For subject discontinue ZS-004 DBRMP due hypo- hyperkalemia baseline potassium value determine within 1 day administration first dose ZS-004E extension study take two ( 2 ) consecutive i-STAT potassium measurement 0 60 minute ( Â± 10 minute ) . If mean i-STAT value 3.5 - 5.5 mmol/l , inclusive , subject enter directly MP receive 10g ZS qd ; mean i-STAT potassium value &gt; 5.5 mmol/l , subject enter AP . If i-STAT potassium value still &gt; 5.0 mmol/l morning AP Study Day 3 , subject enter MP refer normal health care provider standard care . If i-STAT potassium value increase 5.5 mmol/l MP treatment 10g qd , dose increase to15g qd . Conversely , S-K decrease 3.0-3.4 mmol/l , inclusive , dose ZS decrease 5g qd , decrement . If subject 5g qd dose still develop blood potassium i-STAT value 3.0 - 3.4mmol , inclusive dose reduce 5g every day . Subjects receive 11 month treatment open-label ZS .</detailed_description>
	<mesh_term>Hyperkalemia</mesh_term>
	<criteria>Provision write informed consent . Completed ZS004 DBRMP Study Day 29 visit discontinue study ZS004 DBRMP due hypo hyperkalemia able start dose ZS004E within two ( 2 ) day last dose Investigational product ZS004 . Subject must iSTAT potassium value 3.5 6.2 mmol/l inclusive ZS004 DBRMP Study Day 29 visit mean iSTAT potassium value two consecutive measurement 0 60 minute Acute Phase Day 1/Maintenance Phase Day 1 3.5 6.2 mmol/l inclusive subject discontinue study ZS004 DBRMP due hypo hyperkalemia . Pseudohyperkalemia sign symptom , excessive fist clench hemolyzed blood specimen , history severe leukocytosis thrombocytosis . Subjects received alternative treatment hyperkalemia participate study ZS004 . Subjects life expectancy le 3 month . Subjects severely physically mentally incapacitated opinion investigator unable perform subject ' task associate protocol . Women pregnant , lactating , plan become pregnant . Subjects diabetic ketoacidosis . Presence condition , opinion investigator , place subject undue risk potentially jeopardize quality data generate . Known hypersensitivity previous anaphylaxis ZS component thereof . Treatment drug device ZS within last 30 day receive regulatory approval time study entry . Subjects cardiac arrhythmia require immediate treatment . Subjects dialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>